This groundbreaking study, conducted by pioneers in bioregenerative medicine and education, uses modern MRI methods to demonstrate a link between cognitive ability and brain volume changes in people with Down Syndrome. These findings suggest that early intervention techniques enhance the quality of life for individuals afflicted. EWBG, known for its groundbreaking work in stem cell therapy, has been at the forefront of this study, working closely with Heidelberg University. This collaboration demonstrates a shared commitment to transforming the care and treatment of Down Syndrome and associated diseases via cutting-edge scientific breakthroughs.

GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck (known as MSD outside the US and Canada). Under the terms of the agreement, GV20 will evaluate its lead investigational program GV20-0251, a first-in-class antibody targeting the novel immune checkpoint IGSF8, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab), in patients with advanced solid tumors in an ongoing Phase I study. https://classic.clinicaltrials.gov/ct2/show/NCT05669430

AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regimen achieved sustained remission compared to 29 percent of patients receiving placebo in combination with a 52-week steroid taper regimen (p=0.0019).

Waiblingen (ots) – Bosch und R-Biopharm investieren zusammen 150 Millionen Euro in die Entwicklung neuer PCR-Tests und in den Vertrieb. Neuartige BioMEMS-Technologie soll bei der Entwicklung eines PCR-Tests für multiresistente gramnegative Bakterien (MRGN) eingesetzt werden. BioMEMS-Chip ermöglicht das zeitgleiche Testen auf bis zu 250 genetische Merkmale in teils weniger als 15 Minuten. Innovativ, dynamisch und […] Weitere Medizintechnik-Partnerschaft: Bosch und R-Biopharm stärken Analyseplattform Vivalytic / Einsatz von innovativer Bosch BioMEMS-Technologie für PCR-Tests auf multiresistente Bakterien geplant

The global Neuroscience Market has been experiencing significant growth, driven by advancements in technology, increasing research activities, and rising prevalence of neurological disorders. According to a recent report, the market size was estimated at USD 42.6 billion in 2022 and is anticipated to reach USD 65.8 billion by 2030, with a compound annual growth rate (CAGR) of 5.6% during the forecast period from 2023 to 2030. The growth of the neuroscience market is driven by several factors. Technological advancements have led to the development of sophisticated neuroimaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and electroencephalography (EEG), enabling better understanding and diagnosis of neurological conditions. Additionally, increasing investments in neuroscience research and drug development have led to the discovery of novel therapies for neurological disorders, further driving market growth. https://www.snsinsider.com/sample-request/3936

Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI’s 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 – May 1, 2024. Medigene to Present at Upcoming Scientific Conferences

EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens due to their strong cross-reactivity with OncoMimics™ peptides Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma

– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting